Introduction
The incidence of sporadic Cutaneous Malignant Melanoma (CMM) is rapidly expanding worldwide, particularly in developed countries [1, 2] . The tumoral growth, progression, and stealthy spread are mainly modulated by the balance between the tumoral cell renewal rate [3] [4] [5] and the apoptosis process. The cell cycle is characterized by a cellular sequential set of molecular events involved in DNA replication and cell division. In a sustained replicative cell system the elapsed time between any given cell division and the next one corresponds to the cell cycle time (T c ). Following mitosis completion, the cell cycle usually enters the G1 phase. However, at a restriction point of this early stage of the replication cycle, the cell either proceeds through the cycle and divides, or enters into a nondividing or quiescent (GO) phase, thereby reducing the proportion of proliferating cells among the neoplastic population. The Growth Fraction (GF) is defined as the proportion of the cell population actually progressing through the cell cycle. GF is reduced by the cell population in the G0 phase. In addition, cell loss occurs in the dividing and nondividing compartments of the tumor through cell death and metastasis. Therefore, the global rate of CMM growth depends upon the mean T c , the GF extent, and the amount of any cell loss [4] .
Generally, the enlarged germinative compartment and its GF in CMM is indicative of a life-threatening neoplastic progression, and is related to the clinical growth rate of the neoplasm [4] . Such assessment helps distinguishing high risk fast-growing CMM characterized by an enlarged GF from those CMM of lower malignancy that behave as slow-growing or growth-stunted neoplasms associated with a restricted GF [4] . The recruitment and progression of CMM cells in the cell cycle of proliferation are associated with loss of some of their controls normally processed by a series of key regulatory molecules. In addition, all these features are likely conditioned by the presence of CMM stem cells, also referred to as tumor-initiating cells [6] .
Some CMM cells undergo self-destruction under programmed cell death [7] . The molecular compounds involved in apoptosis encompass the combination of positive (pro-apoptotic) and negative (anti-apoptotic) regulators [5] [6] [7] . The former include p53, Bid, Fas/FasL, Noxa, PUMA, Bax, TNF, TRAIL, PITSLRE, interferons, and c-KIT/SCF. The latter include Bcl-2, Bcl-X L , Mcl-1, NF-K B, survivin, livin, ML-IAP as cell as BRAF activation, and NRAS activation. Alternatively, some molecules such as TRAF-2, c-Myc, endothelins, and integrins exhibit either proor anti-apoptotic effects [7] . Some of these compounds were presented as potential therapeutic agents namely, (a) p53 influencing resistance to chemotherapy; (b) Mcl-1 and Bcl-X L overriding apoptosis; (c) TRAIL, exhibiting selective fatal effects on neoplastic cells; (d) NF-K B downregulation sensitizing cells to TRAIL and TNF; (e) PITSLRE kinase alterations leading to Fas resistance; (f) interferons sensitizing cells to other factors; and (g) some inhibitors of apoptosis proteins (IAP) including survivin [7] .
SURVIVIN as an IAP IN CMM
A number of primary changes in CMM tend to suppress apoptosis. Reduced apoptosis is selected in advanced CMM
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A small compound of the IAP family is survivin. Its expression is regulated during development. It is widely expressed in fetal tissues and becomes silent in most adult tissues, although it is reexpressed in a number of cancers. Distinct intracellular pools of survivin are dispersed in the cytosol, mitochondriae, and nucleus [8] . These subcellular pools are probably tied to distinct cell functions. Nuclear survivin is present in a large subset of CMM. Such presence is correlated with poor survival [9] . The nuclear pool is linked to survivin function in mitosis, while the cytosolic and mitochondrial pools are involved its antiapoptotic function. Globally, in neoplastic cells, survivin is predominantly bound to the inner mitochondrial membrane. This IAP is present in CMM and melanocytic nevi, but not in the regular melanocytes. Following some apoptotic stimuli, this IAP is trafficked from mitochondriae into the cytosol. Surviving binds to caspase 3 and 7, and is associated with mitotic spindle where it overrides the M/G2 apoptotic checkpoint [10] . Survivin is a Chromosomal Passenger Protein (CPP) [11] interacting with other specific intracellular molecular components [12] . It pronotes migration of the CPP complex from the inner centromere during prometaphase cytokinesis [13] .
Moecular profiding has identified survivin as a marker of poor prognosis in cancerology [8] . Disruption of survivin functions, particularly in malignancies leads to a series of cell cycle defects including multipolar mitotic spindles, failure of cytokinesis, and formation of multinucleated cells [7] . The presence of a dominant-negative survivin mutant in CMM cells is responsible for a reduction in DNA content during the M and G2 phases, and an impaired proliferation [7] . In addition, survivin is involved in microtubule spindle organization [14] . Likely, it helps CMM cells with DNA damages to bypass specific cell cycle checkpoints, proceeds with cell division and distinctly exerts its anti-apoptotic function. Survivin anti-apoptotic control follows binding to and stabilizing XIAP, which inhibits caspase-9 [15] . Survivin-mediated inhibition of caspase-9 further relies on binding to the Hepatitis B X-Interacting Protein (HBXIP) [16] . Upon triggering the apoptotic pathway, the survivin anti-apoptotic function is downregulated following the release of second mitochondrial-derived activator of caspase (Smac) [17] . Survivin blocks both caspase-dependent and -independent cell death in human melanocytes [18] . In CMM cells, this agent protects against caspase-independent apoptosis [19] . The pro-apoptotic activity of dominant-negative survivin mutants in CMM cells reduces CMM tumor growth [7, 20, 21] .
Cancerogenesis globally involves the successive steps of initiation, promotion and progression phases [22, 23] . In CMM, cell migration, thigmotropism, and tensegrity are likely involved and linked in part to tumor progression and metastasis. The concept of CMM thigmotropism encompasses the complex migration path including the extravascular and (peri) neural spreads. The peculiar involvement of CMM stem cells [6] and the nature of the microenvironmental niche in the thigmotropic process are largely unknown. However, pertinent role of the host milieu and/or the microenvironment in tumorigenesis has also been recognized for CMM [6] . Cell mobility and migration in combination with cell proliferation are activated in both the primary CMM and in the metastatic spread [21, 24, 25] . Cell motility encompasses migration, thigmotropism and invasion, which are key aspects of the metastatic process. They require a set of signalling events both inside CMM cells and in the extracellular matrix for migration of cells within their close microenvironment and to distant sites [26, 27] . Survivin is likely involved in these processes, and possibly plays a role in promoting CMM metastases [21] . Survivin-mediated invasion appears as integrin-independent, but requires activation of nuclear factor (NF) -χB and cell motility kinases, Focal Adhesion Kinase (FAK) and Sarcoma-Related (Src) kinase [7, 28] . Such a complex mechanism enhances cell migration, and promotes the invasive pattern of human CMM cells [29] . Promoting CMM cell mobility appears to follow the activation of the protein kinase-B (Akt) signalling pathway, and the upregulation of α5 integrin [21] . Both events follow survivin overexpression in CMM cells [29] . Survivin knockdown by RNAi, under conditions where apoptosis is not induced, further demonstrate that survivin is required for the constitutive migration and invasion of CMM cells [29] . In addition, survivin-mediated promotion of CMM cell invasion depends on activation of the MAPK pathway [21, 30] .
Conclusion
The majority of CMM-associated deaths are due to metastases, highlighting the importance of understanding the molecular mechanisms driving CMM and progression. Tumorigenesis and metastatic spread of CMM are largely unpredictable by clinical inspection alone [31] and any site of the body is possibly involves. The main factors linked to the metastatic neoplasm are interacting in different ways among patients. They include cell renewal, apoptosis and thigmotropism. These functions are mediated by a number of molecular controls including the IAP survivin, and some immune functions [32] .
The impact of survivin in the overt metastatic CMM spread does not explain the distinct patterns of metastasis distributions in the human body. Locoregional metastases contain tumor in regional lymph nodes and regional cutaneous metastases between the primary tumor and the regional lymph nodes. The latter correspond in called satellite and in-transit metastases. Satellite metastases are separated from the initial stromal tumor by tissue confined around the primary tumor. In-transit metastases are located outside a 2 cm distance. The distinction between satellite and in-transit metastases remains arbitrary. No substantial difference in survival outcome has been reported between satellite and in-transit metastases have similar prognostic value in the recent AJCC staging system. The smoldering pattern of CMM metastases is another rare condition were metastases are confined to a retricted body area (the ley) where metastases waxe and wane over time [5, 29] .
Altogether, the reported features listed in this review indicate that the IAP survivin plays a prominent role in the spreading of
